BioMed X and Sanofi begin joint research on AI-driven drug development
BioMed X has announced that it has begun a joint research project with Sanofi on artificial intelligence (AI)-driven drug development.…
All articles by Aidan McNamee
Aidan McNamee
Aidan joined Pharmaceutical Technology as a trainee reporter in 2023. With a background in data journalism, he has worked in consumer media covering a wide range of topics, and has a particular interest in big data, AI and the metaverse. Previously, Aidan worked with the Reach Data Unit as part of the Google News Initiative fellowship, and graduated with an MSc in Computational and Data Journalism from Cardiff University in 2022.
-
-
BioMarin’s $2.9m haemophilia gene therapy secures FDA approval
BioMarin’s Roctavian has finally received FDA approval following previous rejections and delays. As a result, Roctavian can now be used…
-
AstraZeneca’s STRIDE shows improved outcomes for liver cancer patients
AstraZeneca has announced impressive results for its STRIDE regimen, delivering significantly improved outcomes for advanced liver cancer patients. The treatment…
-
Lantidra wins FDA approval as first-ever type 1 diabetes cell therapy
The US Food and Drug Administration (FDA) has announced that Lantidra, a cellular therapy for type 1 diabetes (T1D), has…
-
Genprex’s Reqorsa gene therapy secures another FDA fast-track designation
Genprex has announced that the US' FDA has granted fast-track designation for Reqorsa, its small cell lung cancer (SCLC) therapy.…
-
Pfizer’s Ngenla finally secures FDA approval following a rocky road to market
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Ngenla (somatrogon-ghla), a paediatric growth hormone deficiency…
-
Pfizer takes on haemophilia B gene therapy market with new FDA application
Pfizer has announced that the US Food and Drug Administration (FDA) has accepted a biologics license application (BLA) for fidanacogene…
-
Rystiggo receives FDA approval, strengthening UCB’s myasthenia gravis portfolio
Belgian biopharmaceutical company UCB has announced that it has received approval from the US Food and Drug Administration (FDA) for…
-
Janssen seeks EMA approval for single tablet pulmonary arterial hypertension treatment
Johnson & Johnson’s Janssen Pharmaceuticals has announced that it is seeking European approval for a pulmonary arterial hypertension (PAH) treatment.…
-
FDA approves first-ever adolescent alopecia treatment from Pfizer
The US Food and Drug Administration (FDA) has approved Pfizer’s Litfulo (ritlecitinib) for treatment of patients as young as 12…